Delving into the Latest Updates on Inactivated SARS-CoV-2 Vaccine (Vero cell)(Chinese Academy of Medical Sciences) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms

COVID-19 Inactivated vaccine(Chinese Academy of Medical Sciences), 科维福

Target

SARS-CoV-2 antigen

Mechanism

SARS-CoV-2 antigen inhibitors

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

Institute of Medical Biology,Chinese Academy of Medical Sciences

Active Organization

Institute of Medical Biology,Chinese Academy of Medical Sciences

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (09 Jun 2021),

COVID-19

RegulationEmergency Use Authorization (CN)

Login to view timeline

ABSTRACTWhile the SARS‐CoV‐2 vaccine offers 70%–95% protection effectiveness against Coronavirus disease 2019 (COVID‐19), a portion of recipients do not produce adequate protective immune responses, particularly, neutralizing antibodies (nAbs). Previous studies of COVID‐19 patients have identified several public antibody lineages, such as IGHV3‐30, IGHV3‐33, IGHV3‐53, IGHV1‐58, and IGHV1‐24. However, it remains unclear how these public antibodies evolve during vaccination or whether there are any special antibody lineages correlated with SARS‐CoV‐2 vaccination. In this study, through a combination of single B cell sequencing and next‐generation sequencing analysis, we systemically studied the dynamic changes of antibody lineages derived from different B cell germlines in their sequence, frequency, and neutralization ability in different vaccinees before and after receiving inactivated SARS‐CoV‐2 vaccines. Our findings indicate that the frequency of antibodies derived from the IGHV4‐34 lineage increased in most individuals after vaccination, and the higher frequency of the antibody usually resulted in stronger binding affinity. Additionally, the ratio of IGHV4‐34 derived antibodies, when compared with other public antibodies, more strongly correlated with the neutralization activity of immune sera from vaccinees. Taken together, these results suggest that IGHV4‐34 is a novel vaccine‐elicited public nAb lineage that plays a crucial role in immune response following inactivated COVID‐19 vaccination.

31 Dec 2023·Emerging Microbes & Infections

Characterizing the cellular and molecular variabilities of peripheral immune cells in healthy recipients of BBIBP-CorV inactivated SARS-CoV-2 vaccine by single-cell RNA sequencing

Article

Author: Qian, Kun ; Tong, Renyang ; Wang, Feng ; Hu, Li ; Liu, Qi ; Zhang, Zheng ; Chen, Alex F. ; Luo, Lingjie ; Pu, Jun ; Shi, Jianfeng ; Shuang, Tian ; Hu, Liuhua ; Sun, Mingze ; Guo, Xiao ; Zhong, Jianmei ; Yuan, Ancai ; Sun, Lingyue ; Zhang, Chenjie ; Zhao, Yichao ; Chen, Yifan ; Lyu, Yuyan ; Lin, Wei ; Li, Zheng ; Li, Ronghong ; Chen, Lei

Over 3 billion doses of inactivated vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been administered globally. However, our understanding of the immune cell functional transcription and T cell receptor (TCR)/B cell receptor (BCR) repertoire dynamics following inactivated SARS-CoV-2 vaccination remains poorly understood. Here, we performed single-cell RNA and TCR/BCR sequencing on peripheral blood mononuclear cells at four time points after immunization with the inactivated SARS-CoV-2 vaccine BBIBP-CorV. Our analysis revealed an enrichment of monocytes, central memory CD4⁺ T cells, type 2 helper T cells and memory B cells following vaccination. Single-cell TCR-seq and RNA-seq comminating analysis identified a clonal expansion of CD4⁺ T cells (but not CD8⁺ T cells) following a booster vaccination that corresponded to a decrease in the TCR diversity of central memory CD4⁺ T cells and type 2 helper T cells. Importantly, these TCR repertoire changes and CD4⁺ T cell differentiation were correlated with the biased VJ gene usage of BCR and the antibody-producing function of B cells post-vaccination. Finally, we compared the functional transcription and repertoire dynamics in immune cells elicited by vaccination and SARS-CoV-2 infection to explore the immune responses under different stimuli. Our data provide novel molecular and cellular evidence for the CD4⁺ T cell-dependent antibody response induced by inactivated vaccine BBIBP-CorV. This information is urgently needed to develop new prevention and control strategies for SARS-CoV-2 infection. (ClinicalTrials.gov Identifier: NCT04871932).

31 Dec 2023·Emerging Microbes & Infections

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial

Article

Author: Wang, Xue ; Chen, Wei ; Tang, Rong ; Jin, Lairun ; Gou, Jinbo ; Cui, Lunbiao ; Wu, Shipo ; Li, Jingxin ; Hou, Lihua ; Chen, Xiaoqin ; Xia, Xin ; Zhong, Jin ; Zhu, Fengcai ; Zhu, Tao ; Feng, Jialu ; Huang, Haitao ; Xu, XiaoYu ; Chen, Yin ; Zhao, Qi ; Li, Zhuopei ; Zhang, Xiaoyin ; Guo, Xiling ; Pan, Hongxing

Antibody persistence and safety up to 12 months of heterologous orally administered adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in individuals who were primed with two-dose inactivated SARS-CoV-2 vaccine (CoronaVac) previously, has not been reported yet. This randomized, open-label, single-centre trial included Chinese adults who have received two-dose CoronaVac randomized to low-dose or high-dose aerosolised Ad5-nCoV group, or CoronaVac group. In this report, we mainly evaluated the geometric mean titres (GMTs) of neutralizing antibodies (NAbs) against live wild-type SARS-CoV-2 virus and omicron BA.4/5 pseudovirus at 12 months after the booster dose and the incidence of serious adverse events (SAEs) till month 12. Of 419 participants, all were included in the safety analysis and 120 (28.64%) were included in the immunogenicity analysis. Serum NAb GMT against live wild-type SARS-CoV-2 was 204.36 (95% CI 152.91, 273.14) in the low-dose group and 171.38 (95% CI 121.27, 242.19) in the high-dose group at month 12, significantly higher than the GMT in the CoronaVac group (8.00 [95% CI 4.22, 15.17], p < 0.0001). Serum NAb GMT against omicron BA.4/5 pseudovirus was 40.97 (95% CI 30.15, 55.67) in the low-dose group and 35.08 (95% CI 26.31, 46.77) in the high-dose group at month 12, whereas the GMT in the CoronaVac group was below the lower limit of detection. No vaccine-related SAEs were observed. Orally administered aerosolised Ad5-nCoV following two-dose CoronaVac priming has a good safety profile and is persistently more immunogenic than three-dose CoronaVac within 12 months after the booster dose.Trial registration: ClinicalTrials.gov identifier: NCT05043259..

100 Deals associated with Inactivated SARS-CoV-2 Vaccine (Vero cell)(Chinese Academy of Medical Sciences)

Login to view more data